Replimune Group Inc

Stock Chart, Company Information, and Scan Results

$11.11(as of Jul 9, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Replimune Group Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$11.11
Ticker SymbolREPL
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees465
CountyUSA
Market Cap$966.2M

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group Inc In Our Stock Scanner

As of Jul 10, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.